{"id":"https://openalex.org/W2118725696","doi":"https://doi.org/10.1089/152091503763816481","title":"Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Agonists for Neurological Disease","display_name":"Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Agonists for Neurological Disease","alternate_titles":[],"publication_year":2003,"publication_date":"2003-02-01","ids":{"openalex":"https://openalex.org/W2118725696","doi":"https://doi.org/10.1089/152091503763816481","mag":"2118725696","pmid":"https://pubmed.ncbi.nlm.nih.gov/12725709"},"language":"en","primary_location":{"id":"doi:10.1089/152091503763816481","doi":"https://doi.org/10.1089/152091503763816481","is_oa":false,"landing_page_url":"https://doi.org/10.1089/152091503763816481","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology &amp; Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2118725696"],"child_works_count":0,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036922002","display_name":"Douglas L. Feinstein","orcid":"https://orcid.org/0000-0003-2815-2885","observed_orcids":["https://orcid.org/0000-0003-2815-2885"]},"institutions":[{"id":"https://openalex.org/I39422238","display_name":"University of Illinois Chicago","ror":"https://ror.org/02mpq6x41","country_code":"US","type":"education","lineage":["https://openalex.org/I39422238"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Douglas L. Feinstein","raw_affiliation_strings":["Department of Anesthesiology, University of Illinois, Chicago, Illinois","Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Anesthesiology, University of Illinois, Chicago, Illinois","institution_ids":["https://openalex.org/I39422238"]},{"raw_affiliation_string":"Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA","institution_ids":["https://openalex.org/I39422238"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5036922002"],"corresponding_institution_ids":["https://openalex.org/I39422238"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":120,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"5","issue":"1","first_page":"67","last_page":"73"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/peroxisome-proliferator-activated-receptors","display_name":"peroxisome proliferator-activated receptors","score":0.9269999861717224},{"id":"https://openalex.org/keywords/ppargamma-agonists","display_name":"PPAR\u03b3 agonists","score":0.8579999804496765},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.9940000176429749},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9879999756813049},{"id":"https://openalex.org/keywords/neuroinflammation","display_name":"neuroinflammation","score":0.8790000081062317},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9890000224113464},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":1.0},{"id":"https://openalex.org/keywords/glial-cells","display_name":"glial cells","score":0.8690000176429749},{"id":"https://openalex.org/keywords/lymphocytes","display_name":"lymphocytes","score":0.7630000114440918},{"id":"https://openalex.org/keywords/anti-inflammatory-activity","display_name":"anti-inflammatory activity","score":0.8709999918937683},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.9129999876022339},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.6809999942779541}],"concepts":[{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.781255841255188},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7002354264259338},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.6993091702461243},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.6140599846839905},{"id":"https://openalex.org/C7341990","wikidata":"https://www.wikidata.org/wiki/Q10331450","display_name":"PPAR agonist","level":4,"score":0.6040979027748108},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5731021761894226},{"id":"https://openalex.org/C4733338","wikidata":"https://www.wikidata.org/wiki/Q2792936","display_name":"Lipid metabolism","level":2,"score":0.5172089338302612},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4784441292285919},{"id":"https://openalex.org/C63932345","wikidata":"https://www.wikidata.org/wiki/Q422500","display_name":"Nuclear receptor","level":4,"score":0.4772210717201233},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.46818673610687256},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.44303956627845764},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41503405570983887},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3896438479423523},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.36962655186653137},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3081204891204834},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.27672260999679565},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2614128589630127},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20893770456314087},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.08632078766822815},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06732529401779175}],"mesh":[{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D014157","descriptor_name":"Transcription Factors","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D018160","descriptor_name":"Receptors, Cytoplasmic and Nuclear","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1089/152091503763816481","doi":"https://doi.org/10.1089/152091503763816481","is_oa":false,"landing_page_url":"https://doi.org/10.1089/152091503763816481","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:12725709","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12725709","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes technology & therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":52,"referenced_works":["https://openalex.org/W1491886022","https://openalex.org/W1545110321","https://openalex.org/W1580962701","https://openalex.org/W1584270516","https://openalex.org/W1633340712","https://openalex.org/W1639924204","https://openalex.org/W1656162023","https://openalex.org/W1909990445","https://openalex.org/W1966012148","https://openalex.org/W1967315954","https://openalex.org/W1967507425","https://openalex.org/W1973557663","https://openalex.org/W1973632746","https://openalex.org/W1981700255","https://openalex.org/W1996267589","https://openalex.org/W1997146656","https://openalex.org/W1998534904","https://openalex.org/W2000520103","https://openalex.org/W2001050980","https://openalex.org/W2015734139","https://openalex.org/W2015903618","https://openalex.org/W2017056299","https://openalex.org/W2019970339","https://openalex.org/W2022840636","https://openalex.org/W2031919883","https://openalex.org/W2037971926","https://openalex.org/W2042983418","https://openalex.org/W2044149565","https://openalex.org/W2045176723","https://openalex.org/W2046454316","https://openalex.org/W2056539006","https://openalex.org/W2057344896","https://openalex.org/W2059030487","https://openalex.org/W2063305853","https://openalex.org/W2068568529","https://openalex.org/W2072502495","https://openalex.org/W2080550827","https://openalex.org/W2088404163","https://openalex.org/W2115352319","https://openalex.org/W2116784956","https://openalex.org/W2135482947","https://openalex.org/W2144473903","https://openalex.org/W2151096273","https://openalex.org/W2157393124","https://openalex.org/W2162162619","https://openalex.org/W2163110760","https://openalex.org/W2253987584","https://openalex.org/W2414440248","https://openalex.org/W2417336082","https://openalex.org/W4230052474","https://openalex.org/W4296759652","https://openalex.org/W4319308372"],"related_works":["https://openalex.org/W2073874214","https://openalex.org/W2040567818","https://openalex.org/W2008938471","https://openalex.org/W2054685711","https://openalex.org/W2090907492","https://openalex.org/W2089405849","https://openalex.org/W2053236602","https://openalex.org/W2004205778"],"abstract_inverted_index":{"Activation":[0],"of":[1,10,15,27,72,89,94,144,153],"peroxisome":[2],"proliferator-activated":[3],"receptors":[4],"(PPARs)":[5],"mediates":[6],"the":[7,23,68,90,103,139,142,149],"insulin-sensitizing":[8],"effects":[9,40,49],"thiazolidinediones":[11,154],"used":[12],"for":[13,92,141],"treatment":[14],"type":[16],"2":[17],"diabetes,":[18],"owing":[19],"to":[20,67,147],"changes":[21],"in":[22,52,75,111,126,155],"transcription":[24],"and":[25,31,46,60,70,83,123,151,161],"expression":[26],"genes":[28],"influencing":[29],"carbohydrate":[30],"lipid":[32],"metabolism.":[33],"However,":[34],"PPAR":[35,106],"activation":[36,65],"can":[37,133],"have":[38,101],"additional":[39,95],"upon":[41],"cellular":[42],"physiology,":[43],"including":[44,56],"anti-proliferative":[45],"anti-inflammatory.":[47],"These":[48],"are":[50],"observed":[51],"many":[53],"cell":[54,120],"types,":[55],"brain":[57],"glial":[58],"cells":[59,63],"blood":[61],"lymphocytes,":[62],"whose":[64],"contributes":[66],"initiation":[69],"progression":[71],"damage":[73],"occurring":[74],"neurological":[76],"diseases":[77],"such":[78,158],"as":[79,159],"Alzheimer's":[80],"disease":[81],"(AD)":[82],"multiple":[84],"sclerosis":[85],"(MS).":[86],"In":[87],"view":[88],"need":[91],"development":[93],"therapeutic":[96],"options,":[97],"several":[98],"recent":[99],"studies":[100,125],"tested":[102],"possibility":[104],"that":[105,130],"agonists":[107,132],"would":[108],"be":[109],"neuroprotective":[110,135],"these":[112],"diseases.":[113],"This":[114],"paper":[115],"will":[116],"summarize":[117],"data":[118],"from":[119,124],"culture":[121],"experiments":[122],"animal":[127],"models,":[128],"demonstrating":[129],"PPARgamma":[131],"exert":[134],"effects,":[136],"thereby":[137],"providing":[138],"basis":[140],"design":[143],"clinical":[145],"trials":[146],"test":[148],"safety":[150],"efficacy":[152],"neuroinflammatory":[156],"conditions":[157],"AD":[160],"MS.":[162]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2118725696","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
